0001209191-18-061329.txt : 20181206 0001209191-18-061329.hdr.sgml : 20181206 20181206170634 ACCESSION NUMBER: 0001209191-18-061329 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181127 FILED AS OF DATE: 20181206 DATE AS OF CHANGE: 20181206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Watts Ryan J. CENTRAL INDEX KEY: 0001724310 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 181221415 MAIL ADDRESS: STREET 1: C/O DENALI THERAPEUTICS INC. STREET 2: 151 OYSTER POINT BLVD., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-27 0 0001714899 Denali Therapeutics Inc. DNLI 0001724310 Watts Ryan J. C/O DENALI THERAPEUTICS INC. 151 OYSTER POINT BOULEVARD, SECOND FLOOR SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Common Stock 12505 D Common Stock 2018-11-27 5 G 0 E 40000 0.00 D 2689304 I See footnote Common Stock 2018-12-03 4 S 0 17933 18.4171 D 2671371 I See footnote Common Stock 2018-12-03 4 S 0 400 19.16 D 2670971 I See footnote The shares were disposed of in connection with a bona fide gift by the Reporting Person to a donor advised fund. The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.05 to $18.86 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.15 to $19.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. /s/ Tyler Nielsen, by power of attorney 2018-12-06